Reporting of Noninferiority and Equivalence Randomized Trials

[1]  Meinhard Kieser,et al.  Quality of reporting of clinical non-inferiority and equivalence randomised trials - update and extension , 2012, Trials.

[2]  P. Kienle,et al.  Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. , 2012, The Lancet. Oncology.

[3]  G. Piaggio,et al.  Active management of the third stage of labour with and without controlled cord traction: a randomised, controlled, non-inferiority trial , 2012, The Lancet.

[4]  Shiro Tanaka,et al.  Statistical Issues and Recommendations for Noninferiority Trials in Oncology: A Systematic Review , 2012, Clinical Cancer Research.

[5]  I. Roberts,et al.  Effect on skin hydration of using baby wipes to clean the napkin area of newborn babies: assessor-blinded randomised controlled equivalence trial , 2011, BMC Pediatrics.

[6]  S. Pocock,et al.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.

[7]  G. Piaggio,et al.  Consort 2010 statement: extension to cluster randomised trials , 2012, BMJ : British Medical Journal.

[8]  K. Suda,et al.  Publication of Noninferiority Clinical Trials: Changes Over a 20‐Year Interval , 2011, Pharmacotherapy.

[9]  V. Skljarevski,et al.  Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. , 2011, Mayo Clinic proceedings.

[10]  Duolao Wang,et al.  Can midlevel health-care providers administer early medical abortion as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal , 2011, The Lancet.

[11]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[12]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[13]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of clinical epidemiology.

[14]  E. Mills,et al.  Reporting of noninferiority and equivalence randomized trials for major prostaglandins: A systematic survey of the ophthalmology literature , 2008, Trials.

[15]  A. Gandjour.  The ethics of non-inferiority trials , 2008, The Lancet.

[16]  C. Chuang-Stein,et al.  The ethics of non-inferiority trials , 2008, The Lancet.

[17]  S. Gillespie,et al.  The ethics of non-inferiority trials , 2008, The Lancet.

[18]  D. Moher,et al.  Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. , 2008, Annals of internal medicine.

[19]  J. Pogue,et al.  Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. , 2008, American heart journal.

[20]  S. Garattini,et al.  Non-inferiority trials are unethical because they disregard patients' interests , 2007, The Lancet.

[21]  R. Willburger,et al.  Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. , 2007, Rheumatology.

[22]  Ludwig A. Hothorn,et al.  An introductory note to the CHMP guidelines: choice of the non‐inferiority margin and data monitoring committees by David Brown, Peter Volkers and Simon Day, Statistics in Medicine 2006; 25:1623–1627 , 2007, Statistics in medicine.

[23]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[24]  Sanjay Kaul,et al.  Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials , 2006, Annals of Internal Medicine.

[25]  Philippe Ravaud,et al.  Quality of reporting of noninferiority and equivalence randomized trials. , 2006, JAMA.

[26]  Sanjay Kaul,et al.  Trials and tribulations of non-inferiority: the ximelagatran experience. , 2005, Journal of the American College of Cardiology.

[27]  D. Gunnell,et al.  Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review , 2005, BMJ : British Medical Journal.

[28]  L. J. Costa,et al.  Negative results in cancer clinical trials--equivalence or poor accrual? , 2004, Controlled clinical trials.

[29]  R. Califf,et al.  Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. , 2004, JAMA.

[30]  Mark Rothmann,et al.  Design and analysis of non‐inferiority mortality trials in oncology , 2002, Statistics in medicine.

[31]  S. Wellek.  Testing Statistical Hypotheses of Equivalence , 2002 .

[32]  P. Cotton,et al.  The virtual colonoscopy study: a large multicenter clinical trial designed to compare two diagnostic screening procedures. , 2002, Controlled clinical trials.

[33]  S. Pocock.  The pros and cons of non-inferiority (equivalence) trials , 2002 .

[34]  G. Piaggio,et al.  Use of the equivalence approach in reproductive health clinical trials , 2001, Statistics in medicine.

[35]  P. Lipsett,et al.  Negative results of randomized clinical trials published in the surgical literature: equivalency or error? , 2001, Archives of surgery.

[36]  E. Topol,et al.  Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. , 2001, The New England journal of medicine.

[37]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[38]  A R Feinstein,et al.  Claims of Equivalence in Medical Research: Are They Supported by the Evidence? , 2000, Annals of Internal Medicine.

[39]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[40]  D. Chadwick.  Safety and efficacy of vigabatrin and carbamazepine in ne wly diagnosed epilepsy: a multicentre randomised double-blind study , 1999, The Lancet.

[41]  I. Olkin,et al.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement. , 1996, JAMA.

[42]  J A Lewis,et al.  Trials to assess equivalence: the importance of rigorous methods , 1996, BMJ.

[43]  D. Moher,et al.  Statistical power, sample size, and their reporting in randomized controlled trials. , 1994, JAMA.

[44]  R. Simon,et al.  Planning and monitoring of equivalence studies. , 1988, Biometrics.